Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02864992 · ClinicalTrials.gov registry record · Phase 2
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
A Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 337
- Enrollment target
- 20
- Study locations
NCT02864992: Active Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, sponsored by EMD Serono Research & Development Institute.
NCT02864992 is a Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 337 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02864992, a Phase 2 study of Lung Adenocarcinoma Stage IIIB/IV and Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 337 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality of life. The study also has an optional pharmacogenetic research part. Pharmacogenetic research is an important way to try to understand the role of genetics in human disease and how genes impact the effectiveness of drugs, because differences in genes can change the way a person responds to a particular drug.
Primary Outcome
Objective response will be determined according to RECIST 1.1 and as per IRC. Objective response was defined as number of participants with either a confirmed complete response (CR) or partial response (PR) from first administration of study treatment to first observation of progressive disease (PD) .CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30 percent (%) reduction from baseline in the sum of the longest diameter (SLD) of all lesions. PD was defined as at
Conditions Studied
Interventions
- DRUG Tepotinib
Study Locations (20)
California
- City of Hope Cancer Center - Duarte
- California Cancer Associates for Research & Excellence, Inc. - Encinitas
- St. Joseph Hospital - Orange
- Torrance Health Association - Redondo Beach
- St Joseph Heritage Healthcare - Santa Rosa
Missouri
- St. Louis Cancer Care, LLP - Bridgeton
- Saint Louis University Cancer Center - St Louis
- Saint Louis University - St Louis
Florida
- Holy Cross Hospital Inc. - Fort Lauderdale
- H. Lee Moffitt Cancer Center and Research Institute, Inc - Tampa
Georgia
- University Cancer & Blood Center, LLC - Athens
- Winship Cancer Institute - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
- Ingalls Hospital - Harvey
New Jersey
- Summit Medical Group, P.A. - Berkeley Heights
- Summit Medical Group - Berkeley Heights
Colorado
- Rocky Mountain Cancer Centers, LLP - Denver
Indiana
- Community Regional Cancer Care - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2026-04-30 |
| Phase | Phase 2 |
What the registry record for NCT02864992 still lists
NCT02864992 is an interventional study that assigns participants to a tested intervention. The registered 337 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (153% higher).
The record links to 2 conditions, with Lung Adenocarcinoma Stage IIIB/IV appearing as the primary indexed condition, and to 1 intervention - of which Tepotinib is the first listed.
NCT02864992 names 20 study sites across 10 states, led by California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT02864992 about?
NCT02864992 is a clinical study titled "Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)". This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how body processes the study drug, or how the study drug affects your quality...
What is the current status of trial NCT02864992?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 337 participants. The study started on 2016-09-13. Estimated completion is 2026-04-30.
What conditions does trial NCT02864992 study?
This clinical trial studies the following conditions: Lung Adenocarcinoma Stage IIIB/IV, Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification.
What interventions are being tested in trial NCT02864992?
The interventions under investigation include: Tepotinib (DRUG).
Who is sponsoring clinical trial NCT02864992?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02864992 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Adenocarcinoma Stage IIIB/IV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02864992's enrollment target sits among peer trials
337 141st of 2000 higher than 1,860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03253263 · 338 participants · Phase 2
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
- NCT05658731 · 338 participants · NA
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
- NCT06022939 · 338 participants · Phase 3
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
- NCT03947385 · 336 participants · Phase 1
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI